GRAIL Faces Securities Class Action After $2.2 Billion Market Plunge
A $2.2 billion collapse in market capitalization has triggered a securities class action against GRAIL, Inc. following the failure of its critical NHS-Galleri cancer detection trial. Investors allege the company misled them about the study's design and the feasibility of its primary endpoint, leading to massive stock losses.
The litigation targets the period between May 13, 2025, and February 19, 2026, during which GRAIL executives repeatedly voiced confidence in the trial’s three-year follow-up structure. The lawsuit, spearheaded by the firm Hagens Berman, claims management failed to disclose internal data suggesting that the chosen timeframe was insufficient to demonstrate a statistically significant reduction in late-stage cancer diagnoses.
On February 19, 2026, the company admitted the trial failed its primary endpoint, conceding that a longer follow-up period likely should have been implemented. The market response was swift, with shares plummeting more than 50% the following day. Hagens Berman partner Reed Kathrein stated the firm is specifically investigating when management became aware that the three-year duration was inadequate compared to their public assurances. Investors who suffered losses have until August 4, 2026, to file as lead plaintiffs.
Comments (0)
No comments yet. Be the first!